Disease Domain | Count |
---|---|
Neoplasms | 9 |
Nervous System Diseases | 7 |
Infectious Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 17 |
Chemical drugs | 1 |
Target |
Mechanism TYMS inhibitors |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date01 Jan 1997 |
Target |
Mechanism COX-1 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc. US |
First Approval Date31 Dec 1987 |
Target |
Mechanism NAAA inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date08 Dec 2024 |
Sponsor / Collaborator |
Start Date01 Sep 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
ARN-16186 ( NAAA ) | Neuritis More | Preclinical |
IIT-24 ( NR1D ) | Melanoma More | Preclinical |
ARN-24139 ( Top II ) | Neoplasms More | Preclinical |
Compound 3m (Air Force Medical University ) ( Top I x Top II ) | COVID-19 More | Preclinical |
ARN21934 ( Top II ) | Neoplasms More | Preclinical |